Medicare Part B Utilization Management Committee Review

UM Committee Review	
Approved Dates	

1. The 2024 Medicare Advantage and Part D Final Rule (CMS-4201-F) specifies that all MA plans establish a Utilization Management (UM) Committee to review all utilization management, including prior authorization, policies annually and ensure they are consistent with the coverage requirements, including current, traditional Medicare's national and local coverage decisions and guidelines. Refer to § 422.137 Medicare Advantage Utilization Management Committee.
2. Medicare payment is contingent upon several determinations, one of which being that an item or service is "reasonable and necessary" for the diagnosis or treatment of an illness or injury, to improve functioning of a malformed body member, or is a covered preventative service.
    a. In order to determine that a drug or biological meets the "reasonable and necessary" requirement, the MA Plan, at its discretion, may apply utilization management criteria.
    b. As FDA-approval of drugs or biologics can occur at any time for new agents as well as additional indications for already approved drugs or biologics, this determination of "reasonable and necessary" may need to occur immediately upon FDA approval and/or market availability/product launch.
    c. To that end, the related document below, based upon original Medicare guidance, shall be relied upon to determine "reasonable and necessary" in these situations.
    d. The UM Committee shall review all agents for which the above has been applied in order to determine "reasonable and necessary" at the next opportunity and no less frequently than annually.

Related Documents

Medicare Part B Utilization Management in the absence of NCD or LCD

References

1. Lexi-Drugs. Lexicomp [Internet]. Hudson, OH: Wolters Kluwer Health, Inc. Available from: http://online.lexi.com
2. Merative Micromedex (DRUGDEX). Micromedex [Internet]. Greenwood Village, CO: Truven Health Analytics, Inc. Available from: http://www.micromedexsolutions.com

© 2024 Prime Therapeutics LLC

3. Gold Standard, Inc. Clinical Pharmacology [Internet]. Philadelphia, PA: Elsevier. Available from: https://www.clinicalkey.com/pharmacology/
4. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc. Available from: https://www.ahfscdi.com/login
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) National Comprehensive Cancer Network, Inc. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.

© 2024 Prime Therapeutics LLC